{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:08:22Z","timestamp":1774386502789,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1988,3,1]],"date-time":"1988-03-01T00:00:00Z","timestamp":573177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[1988,3,1]],"date-time":"1988-03-01T00:00:00Z","timestamp":573177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Oncol. &amp; Tumor Pharmacother."],"published-print":{"date-parts":[[1988,3]]},"DOI":"10.1007\/bf03003180","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T18:21:13Z","timestamp":1631902873000},"page":"41-47","source":"Crossref","is-referenced-by-count":41,"title":["Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia"],"prefix":"10.1007","volume":"5","author":[{"given":"U.","family":"Jehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"G\u00f6ldel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rienm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Wilmanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03003180_CR1","first-page":"1587","volume":"42","author":"A P Early","year":"1982","unstructured":"Early A P, Preisler H D, Slocum Het al: A pilot study of high dose l-beta-O-arabinofuranosylcytosine for acute leukemia and refractory lymphoma \u2014 clinical response and pharmacology.Cancer Res\n                           42, 1587 (1982).","journal-title":"Cancer Res"},{"key":"BF03003180_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.2830160108","volume":"16","author":"G Cantin","year":"1984","unstructured":"Cantin G, Brennan J: High dose cytosine arabinoside for acute nonlymphocytic leukemia.Am J Hemat\n                           16, 59 (1984).","journal-title":"Am J Hemat"},{"key":"BF03003180_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM198301063080105","volume":"308","author":"H Preisler","year":"1983","unstructured":"Preisler H, Early A, Raza Aet al. Therapy of secondary acute nonlymphocytic leukemia with cytarabine.New Engl J Med\n                           308, 21 (1983).","journal-title":"New Engl J Med"},{"key":"BF03003180_CR4","first-page":"694","volume":"63","author":"R Capizzi","year":"1084","unstructured":"Capizzi R, Poole M, Cooper M Ret al: Treatment of poor risk acute leukemia with sequential high-dose Ara C and asparaginase.Blood\n                           63, 694, 1084.","journal-title":"Blood"},{"key":"BF03003180_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0277-5379(84)90201-3","volume":"20","author":"H Preisler","year":"1984","unstructured":"Preisler H: High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia.Eur J Cancer clin Oncol\n                           20, 297 (1984).","journal-title":"Eur J Cancer clin Oncol"},{"key":"BF03003180_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O","volume":"44","author":"S A Rudnick","year":"1979","unstructured":"Rudnick S A, Cadman E C, Capizzi RLet al: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.Cancer\n                           44, 1189 (1979).","journal-title":"Cancer"},{"key":"BF03003180_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","volume":"62","author":"R H Herzig","year":"1983","unstructured":"Herzig R H, Wolff S N, Lazarus HMet al: High-dose cytosine arabinoside therapy for refractory leukemia.Blood\n                           62, 361 (1983).","journal-title":"Blood"},{"key":"BF03003180_CR8","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z","volume":"48","author":"H Lazarus","year":"1981","unstructured":"Lazarus H, Herzig R, Herzig Get al: Central nervous system toxicity of high dose systemic cytosine arabinoside.Cancer\n                           48, 2577 (1981).","journal-title":"Cancer"},{"key":"BF03003180_CR9","first-page":"1","volume":"222","author":"R Spector","year":"1982","unstructured":"Spector R: Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.J Pharmac exp Ther\n                           222, 1 (1982).","journal-title":"J Pharmac exp Ther"},{"key":"BF03003180_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ana.410140505","volume":"14","author":"M Winkelman","year":"1983","unstructured":"Winkelman M, Hines J D: Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study.Ann Neurol\n                           14, 520 (1983).","journal-title":"Ann Neurol"},{"key":"BF03003180_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/1097-0142(19830201)51:3<430::AID-CNCR2820510313>3.0.CO;2-5","volume":"51","author":"P Ritch","year":"1983","unstructured":"Ritch P, Hansen R, Heuer D: Ocular toxicity from high-dose cytosine arabinoside.Cancer\n                           51, 430 (1983).","journal-title":"Cancer"},{"key":"BF03003180_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mpo.2950110416","volume":"11","author":"J Pizzuto","year":"1983","unstructured":"Pizzuto J, Aviles A, Ramos Eet al: Cytosine arabinoside induced liver damage. Histopathologic demonstration.Med pediatr Oncol\n                           11, 287 (1983).","journal-title":"Med pediatr Oncol"},{"key":"BF03003180_CR13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/1097-0142(19851015)56:8<1940::AID-CNCR2820560808>3.0.CO;2-N","volume":"56","author":"R F Siemers","year":"1985","unstructured":"Siemers R F, Friedenberg W R, Norfleet R G: High-dose cytosine arabinoside-associated pancreatitis.Cancer\n                           56, 1940 (1985).","journal-title":"Cancer"},{"key":"BF03003180_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/1097-0142(197810)42:4<1747::AID-CNCR2820420413>3.0.CO;2-T","volume":"42","author":"R E Slavin","year":"1978","unstructured":"Slavin R E, Dias M A, Saral R: Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols.Cancer\n                           42, 1747 (1978).","journal-title":"Cancer"},{"key":"BF03003180_CR15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1985.3.5.607","volume":"3","author":"H Johnson","year":"1985","unstructured":"Johnson H, Smith T, Desforges J: Cytosinearabinoside-induced colitis and peritonitis: non-operative management.J clin Oncol\n                           3, 607 (1985).","journal-title":"J clin Oncol"},{"key":"BF03003180_CR16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.1984.tb02898.x","volume":"57","author":"H van Prooyen","year":"1984","unstructured":"van Prooyen, H, Dekker A, Punt K: The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukemia in relapse.Br J Haemal\n                           57, 291 (1984).","journal-title":"Br J Haemal"},{"key":"BF03003180_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.1985.tb00748.x","volume":"34","author":"R Willemze","year":"1985","unstructured":"Willemze R, Peters W G, van Hennik MBet al: Intermediate and high-dose Ara C and m-Amsa (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukemia and lymphoblastic non-Hogkin lymphoma.Scand J Haemal\n                           34, 83 (1985).","journal-title":"Scand J Haemal"},{"key":"BF03003180_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.1985.3.5.613","volume":"3","author":"L Dworkin","year":"1985","unstructured":"Dworkin L, Goldman R, Zivin Let al: Cerebellar toxicity following high-dose Ara-C.J clin Oncol\n                           3, 613 (1985).","journal-title":"J clin Oncol"},{"key":"BF03003180_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0002-9343(81)90759-2","volume":"70","author":"H Haupt","year":"1981","unstructured":"Haupt H, Hutchins G, Moore G: Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.Am J Med\n                           70, 250 (1981).","journal-title":"Am J Med"},{"key":"BF03003180_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1056\/NEJM198608283150904","volume":"315","author":"F P Ognibene","year":"1986","unstructured":"Ognibene F P, Martin S E, Parker MMet al: Adult respiratory distress syndrome in patients with severe neutropenia.New Engl J Med\n                           315, 547 (1986).","journal-title":"New Engl J Med"},{"key":"BF03003180_CR21","first-page":"483","volume":"66","author":"L J Steinherz","year":"1982","unstructured":"Steinherz L J, Steinherz P G, Mangiacasale Det al: Cardiac abnormalities after AMSA administration.Cancer treat Rep\n                           66, 483 (1982).","journal-title":"Cancer treat Rep"},{"key":"BF03003180_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/1097-0142(19860401)57:7<1284::AID-CNCR2820570705>3.0.CO;2-#","volume":"57","author":"K Lindpaintner","year":"1986","unstructured":"Lindpaintner K, Lindpaintner L S, Wentworth Met al: Acute myocardial necrosis during administration of amsacrine.Cancer\n                           57, 1284 (1986).","journal-title":"Cancer"},{"key":"BF03003180_CR23","first-page":"215","volume":"26","author":"R Willemze","year":"1983","unstructured":"Willemze R, Fibbe W E, Zwand F E: Experience with intermediate and high dose arabinoside in relapsed and refractory acute leukemia.Neth J Med\n                           26, 215 (1983).","journal-title":"Neth J Med"},{"key":"BF03003180_CR24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/1097-0142(19851101)56:9<2181::AID-CNCR2820560907>3.0.CO;2-B","volume":"56","author":"B S Andersson","year":"1985","unstructured":"Andersson B S, Cogan B M, Keating M Jet al: Subacute pulmonary failure complicating therapy with high-dose Ara C in acute leukemia.Cancer\n                           56, 2181 (1985).","journal-title":"Cancer"}],"container-title":["Medical Oncology and Tumor Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03003180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03003180\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03003180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T19:24:38Z","timestamp":1631906678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF03003180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1988,3]]}},"alternative-id":["BF03003180"],"URL":"https:\/\/doi.org\/10.1007\/bf03003180","relation":{},"ISSN":["0736-0118"],"issn-type":[{"value":"0736-0118","type":"print"}],"subject":[],"published":{"date-parts":[[1988,3]]}}}